


Genelux Revenue
Biotechnology Research • Westlake Village, California, United States • 21-50 Employees
Genelux revenue & valuation
| Annual revenue | $32,000 |
| Revenue per employee | $1,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $102,400 |
| Total funding | $56,000,000 |
Key Contact at Genelux
Erika Klatt
Director, Plant Manager
Company overview
| Headquarters | Westlake Village, California, United States |
| Phone number | +18052679889 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Founded | 2001 |
| Employees | 21-50 |
| Socials |
Genelux Email Formats
Genelux uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@genelux.com), used 58.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@genelux.com | 58.3% |
{first name}.{last name} | john.doe@genelux.com | 33.3% |
{first initial} | j@genelux.com | 8.3% |
About Genelux
Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of the vaccinia virus. Olvi-Vec, our lead product candidate is currently in a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed in Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer. We are dedicated to advancing a pipeline of next-generation oncolytic immunotherapies that deliver the full complement of tumor neo-antigens with the power to stimulate a personalized immune response for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Information about our investigational products and clinical trials can be found here. For more information, please visit https://genelux.com/ and follow us on Twitter @Genelux_Corp and Facebook @Genelux. Olvi-Vec is an investigational product candidate not yet approved by the US Food and Drug Administration.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Genelux has 13 employees across 5 departments.
Departments
Number of employees
Funding Data
Explore Genelux's funding history, including investment rounds, total capital raised, and key backers.
Genelux Tech Stack
Discover the technologies and tools that power Genelux's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Video players
JavaScript libraries
Caching
JavaScript libraries
Analytics
JavaScript libraries
Web servers
JavaScript libraries
Programming languages
Blogs
Analytics
Frequently asked questions
4.8
40,000 users



